Medacta’s current Executive Vice President, Francesco Siccardi, will become the company’s next chief executive officer in November 2018. Founder Dr. Alberto Siccardi will transition to President of the Board of Directors.
Francesco Siccardi joined the company in 2002 and has served in his present position since 2010. As a biomechanical engineer by training, he participated in the development of numerous key products such as AMIS® (Anterior Minimally Invasive Surgery) total hips, GMK® Sphere total knees, MyKnee® Patient-Matched Technology, single use instruments and the Medacta Shoulder System.
Medacta is #13 in ORTHOWORLD’s estimates of orthopaedic device companies ranked by revenue. For 2017, ORTHOWORLD estimated Medacta’s revenue at US $278.1MM, growth of 12% vs. 2016. Joint reconstruction accounts for over 95% of that; the remainder of the company’s revenue derives from spine products. Medacta will enter the U.S. soft tissue repair/sports medicine market with the M-ARS ACL: Anatomic Ribbon Surgery System, which received U.S. FDA 510(k) clearance in early 4Q17.
Mr. Siccardi was instrumental in the creation of Medacta’s Spine and Sports Medicine divisions.
Medacta's current Executive Vice President, Francesco Siccardi, will become the company's next chief executive officer in November 2018. Founder Dr. Alberto Siccardi will transition to President of the Board of Directors.
Francesco Siccardi joined the company in 2002 and has served in his present position since 2010. As a biomechanical...
Medacta’s current Executive Vice President, Francesco Siccardi, will become the company’s next chief executive officer in November 2018. Founder Dr. Alberto Siccardi will transition to President of the Board of Directors.
Francesco Siccardi joined the company in 2002 and has served in his present position since 2010. As a biomechanical engineer by training, he participated in the development of numerous key products such as AMIS® (Anterior Minimally Invasive Surgery) total hips, GMK® Sphere total knees, MyKnee® Patient-Matched Technology, single use instruments and the Medacta Shoulder System.
Medacta is #13 in ORTHOWORLD’s estimates of orthopaedic device companies ranked by revenue. For 2017, ORTHOWORLD estimated Medacta’s revenue at US $278.1MM, growth of 12% vs. 2016. Joint reconstruction accounts for over 95% of that; the remainder of the company’s revenue derives from spine products. Medacta will enter the U.S. soft tissue repair/sports medicine market with the M-ARS ACL: Anatomic Ribbon Surgery System, which received U.S. FDA 510(k) clearance in early 4Q17.
Mr. Siccardi was instrumental in the creation of Medacta’s Spine and Sports Medicine divisions.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
